PE20001286A1 - FORMULACIONES FARMACEUTICAS DE LIBERACION CONTROLADA DE INHIBIDORES DE GMPc PDE-5 - Google Patents
FORMULACIONES FARMACEUTICAS DE LIBERACION CONTROLADA DE INHIBIDORES DE GMPc PDE-5Info
- Publication number
- PE20001286A1 PE20001286A1 PE1999001062A PE00106299A PE20001286A1 PE 20001286 A1 PE20001286 A1 PE 20001286A1 PE 1999001062 A PE1999001062 A PE 1999001062A PE 00106299 A PE00106299 A PE 00106299A PE 20001286 A1 PE20001286 A1 PE 20001286A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- release
- hipromele
- gmpc
- refers
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000013270 controlled release Methods 0.000 title abstract 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 title 1
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- -1 HYDROXYPROPYL Chemical class 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical compound [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 230000003628 erosive effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMULACION DE LIBERACION SOSTENIDA Y CONTROLADA ORAL QUE CONTIENE DE 5% A 50% DE UN INHIBIDOR DE GMPc PDE5 QUE NO ES ESENCIALMENTE SILDENAFIL, OXIDO DE POLIETILENO DE BAJO PESO MOLECULAR, HIDROXIPROPIL HIPROMELOSA DE PESO MOLECULAR 80 000 A 250 000; CON UN GRADO DE SUSTITUCION METILO EN EL INTERVALO DEL 19% AL 30%; POLIMEROS ENTERICOS; LIBERANDOSE EL 75% EN PESO DEL INHIBIDOR EN EL TRACTO GASTROINTESTINAL DESPUES DE UN PERIODO DE 1 A 24 HORAS DESPUES DE LA ADMINISTRACION; EL INHIBIDOR DE GMPc PDE-5 SE ENCUENTRA i)INCRUSTADO EN UNA MATRIZ DE LA CUAL SE LIBERA POR DIFUSION O EROSION; ii)PRESENTE EN UN NUCLEO QUE SE RECUBRE CON UNA MEMBRANA CONTROLADORA DE LA VELOCIDAD DE LIBERACION LA QUE COMPRENDE UN COPOLIMERO DE METACRILATO DE AMONIO Y UN PLASTIFICANTE; iii)EN UN NUCLEO CON UN RECUBRIMIENTO EXTERNO IMPERMEABLE QUE PRESENTA UNA ABERTURA PARA LIBERAR EL INHIBIDOR; LA FORMULACION CONTIENE ADEMAS UN AGENTE TAMPONANTE; UN RECUBRIMIENTO COSMETICO; SIENDO LA VELOCIDAD DE LIBERACION INDEPENDIENTE DEL pH. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DISFUNCION SEXUAL
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9823192.1A GB9823192D0 (en) | 1998-10-23 | 1998-10-23 | Pharmaceutical formulations |
| GBGB9825117.6A GB9825117D0 (en) | 1998-11-16 | 1998-11-16 | Pharmaceutical formulations |
| GBGB9826392.4A GB9826392D0 (en) | 1998-11-27 | 1998-11-27 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001286A1 true PE20001286A1 (es) | 2000-11-22 |
Family
ID=27269526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999001062A PE20001286A1 (es) | 1998-10-23 | 1999-10-21 | FORMULACIONES FARMACEUTICAS DE LIBERACION CONTROLADA DE INHIBIDORES DE GMPc PDE-5 |
Country Status (44)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135462A0 (en) * | 1997-11-12 | 2001-05-20 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| CN100444830C (zh) | 1998-11-02 | 2008-12-24 | 伊兰公司，Plc | 多颗粒改进释放组合物 |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| RU2230556C2 (ru) | 1999-10-29 | 2004-06-20 | Эро-Селтик, С.А. | Препаративные формы гидрокодона с контролируемым высвобождением |
| US7501409B2 (en) | 2000-09-06 | 2009-03-10 | Mitsubishi Tanabe Pharma Corporation | Preparations for oral administration |
| HU230875B1 (hu) | 2000-10-30 | 2018-11-29 | Euro-Celtique S.A. | Szabályozott hatóanyag-leadású hidrokodon készítmények |
| US7927623B2 (en) | 2001-02-15 | 2011-04-19 | Mitsubishi Tanabe Pharma Corporation | Tablets quickly disintegrated in oral cavity |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| ITMI20020515A1 (it) * | 2002-03-12 | 2003-09-12 | Jagotec Ag | Sistema per il rilasco controllato di uno o piu' principi attivi |
| GB0318824D0 (en) * | 2003-08-11 | 2003-09-10 | Glaxo Group Ltd | Novel composition |
| PT1750766E (pt) | 2004-05-11 | 2013-09-30 | Emotional Brain Bv | Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina |
| DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| GB0421121D0 (en) * | 2004-09-22 | 2004-10-27 | Natrocell Technologies Ltd | Composite rodenticide |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
| DE102005009241A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit kontrollierter Bioverfügbarkeit |
| DE102005009240A1 (de) | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
| EP1896076A2 (en) * | 2005-06-27 | 2008-03-12 | Daniel Drai | Compositions and methods for enhancement of sexual function |
| PL1912650T3 (pl) | 2005-08-03 | 2018-01-31 | Sprout Pharmaceuticals Inc | Zastosowanie flibanseryny w leczeniu otyłości |
| RU2435588C2 (ru) * | 2005-09-29 | 2011-12-10 | Байер Шеринг Фарма Акциенгезельшафт | Ингибиторы фдэ и их комбинации для лечения урологических расстройств |
| WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| CA2660476C (en) | 2006-08-14 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| KR20090045945A (ko) | 2006-08-25 | 2009-05-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 제어 방출 시스템 및 이의 제조방법 |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| WO2008115797A1 (en) * | 2007-03-16 | 2008-09-25 | Pavo, Inc. | Therapeutic compositions and methods |
| JP2010532319A (ja) * | 2007-06-13 | 2010-10-07 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 聴覚障害の処置用のｐｄｅ阻害剤 |
| CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| US20110033506A1 (en) * | 2008-02-08 | 2011-02-10 | Adel Penhasi | Combination dosage form of low-dose modafinil and low-dose sildenafil |
| WO2010067140A1 (es) | 2008-12-12 | 2010-06-17 | Siegfried Rhein S.A. De C.V. | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla |
| KR101004205B1 (ko) * | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
| EA015250B9 (ru) * | 2010-11-19 | 2013-10-30 | Тева Фармасьютикал Индастриз, Лтд. | Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления |
| EP2709597A2 (en) | 2011-05-13 | 2014-03-26 | Emotional Brain B.V. | Drug delivery system |
| WO2013016144A1 (en) * | 2011-07-22 | 2013-01-31 | Pom Wonderful, Llc | Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith |
| WO2017168174A1 (en) * | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| CN113995727B (zh) * | 2021-11-08 | 2023-04-07 | 山东鲁抗医药股份有限公司 | 一种5型磷酸二酯酶抑制剂片剂及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| JPS54119021A (en) * | 1978-03-06 | 1979-09-14 | Nippon Kayaku Co Ltd | Carcinostatic agent |
| CH648754A5 (en) * | 1979-08-16 | 1985-04-15 | Ciba Geigy Ag | Pharmaceutical slow release tablet |
| JPS5748908A (en) * | 1980-09-08 | 1982-03-20 | Kyorin Pharmaceut Co Ltd | Prolonged release type nicomol pharmaceutical |
| FR2624732B1 (fr) | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
| MC2025A1 (fr) * | 1988-04-20 | 1990-04-25 | Asta Pharma Ag | Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee |
| IT1229856B (it) * | 1989-04-20 | 1991-09-13 | Recordati Chem Pharm | Compresse a rilascio controllato contenenti flavossato. |
| US5474784A (en) | 1990-03-02 | 1995-12-12 | British Technology Group Limited | Dispensing device |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
| DK0621032T3 (da) * | 1993-04-23 | 2000-10-23 | Novartis Ag | Lægemiddelform med reguleret afgivelse |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
| US5656629A (en) * | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
| US5888534A (en) | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| GB9523752D0 (en) * | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
| JPH1067657A (ja) * | 1996-06-18 | 1998-03-10 | Otsuka Pharmaceut Co Ltd | マルチプルユニット型持続性製剤 |
| AU2976897A (en) * | 1996-06-18 | 1998-01-07 | Otsuka Pharmaceutical Co., Ltd. | Multiple-unit type prolonged action drug preparation |
| CA2277017C (en) * | 1997-01-06 | 2002-11-26 | Pfizer Inc. | Rapidly releasing and taste-masking pharmaceutical dosage form |
| US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6277884B1 (en) * | 1998-06-01 | 2001-08-21 | Nitromed, Inc. | Treatment of sexual dysfunction with N-hydroxyguanidine compounds |
| ES2220109T3 (es) * | 1998-09-04 | 2004-12-01 | Ortho-Mcneil Pharmaceutical, Inc. | 5-heterociclilpirazolo (4,3-d) pirimidin-7-onas para el tratamiento de la disfuncion erectil masculina. |
-
1999
- 1999-04-10 UA UA2001042718A patent/UA67802C2/uk unknown
- 1999-10-01 TW TW088116973A patent/TW577756B/zh not_active IP Right Cessation
- 1999-10-04 HR HR20010285A patent/HRP20010285A2/xx not_active Application Discontinuation
- 1999-10-04 PL PL99347476A patent/PL195789B1/pl not_active IP Right Cessation
- 1999-10-04 CN CN99812510A patent/CN1324233A/zh active Pending
- 1999-10-04 SK SK519-2001A patent/SK286473B6/sk unknown
- 1999-10-04 ES ES99946377T patent/ES2272082T3/es not_active Expired - Lifetime
- 1999-10-04 JP JP2000577993A patent/JP2002528408A/ja active Pending
- 1999-10-04 IL IL141764A patent/IL141764A/en unknown
- 1999-10-04 EA EA200100298A patent/EA004068B1/ru not_active IP Right Cessation
- 1999-10-04 PT PT99946377T patent/PT1123088E/pt unknown
- 1999-10-04 CZ CZ20011427A patent/CZ20011427A3/cs unknown
- 1999-10-04 CA CA002348086A patent/CA2348086C/en not_active Expired - Fee Related
- 1999-10-04 DE DE69933383T patent/DE69933383T2/de not_active Expired - Fee Related
- 1999-10-04 AP APAP/P/2001/002125A patent/AP2001002125A0/en unknown
- 1999-10-04 NZ NZ510275A patent/NZ510275A/en unknown
- 1999-10-04 BR BR9914718-1A patent/BR9914718A/pt not_active Application Discontinuation
- 1999-10-04 MX MXPA01004011A patent/MXPA01004011A/es active IP Right Grant
- 1999-10-04 HU HU0104318A patent/HUP0104318A3/hu unknown
- 1999-10-04 WO PCT/IB1999/001619 patent/WO2000024383A1/en not_active Ceased
- 1999-10-04 OA OA1200100093A patent/OA11664A/en unknown
- 1999-10-04 AT AT99946377T patent/ATE340562T1/de not_active IP Right Cessation
- 1999-10-04 EP EP99946377A patent/EP1123088B1/en not_active Expired - Lifetime
- 1999-10-04 AU AU58787/99A patent/AU756509B2/en not_active Ceased
- 1999-10-04 DK DK99946377T patent/DK1123088T3/da active
- 1999-10-04 HK HK02103588.0A patent/HK1041818A1/zh unknown
- 1999-10-04 KR KR1020017005042A patent/KR20010075659A/ko not_active Ceased
- 1999-10-04 EE EEP200100235A patent/EE200100235A/xx unknown
- 1999-10-04 ID IDW20010891A patent/ID28232A/id unknown
- 1999-10-04 TR TR2001/01103T patent/TR200101103T2/xx unknown
- 1999-10-18 PA PA19998484301A patent/PA8484301A1/es unknown
- 1999-10-20 MY MYPI99004535A patent/MY130727A/en unknown
- 1999-10-20 DZ DZ990223A patent/DZ2923A1/xx active
- 1999-10-20 MA MA25820A patent/MA26700A1/fr unknown
- 1999-10-21 PE PE1999001062A patent/PE20001286A1/es not_active Application Discontinuation
- 1999-10-22 CO CO99066970A patent/CO5160262A1/es unknown
- 1999-10-22 US US09/425,622 patent/US6964780B1/en not_active Expired - Fee Related
- 1999-10-22 UY UY25765A patent/UY25765A1/es not_active Application Discontinuation
- 1999-10-22 GT GT199900184A patent/GT199900184A/es unknown
-
2001
- 2001-02-27 IS IS5865A patent/IS5865A/is unknown
- 2001-03-14 CR CR6326A patent/CR6326A/es not_active Application Discontinuation
- 2001-04-19 NO NO20011933A patent/NO20011933L/no not_active Application Discontinuation
- 2001-04-24 BG BG105465A patent/BG65323B1/bg unknown
-
2006
- 2006-11-13 CY CY20061101644T patent/CY1106239T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20001286A1 (es) | FORMULACIONES FARMACEUTICAS DE LIBERACION CONTROLADA DE INHIBIDORES DE GMPc PDE-5 | |
| ATE374601T1 (de) | Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein- wirkstoffe, sowie ein verfahren zur herstellung der arzneiform | |
| CO6270385A2 (es) | Bromhidrato de bupropion y aplicaciones terapeuticas | |
| WO2005079752A3 (en) | Controlled release pharmaceutical compositions with improved bioavailability | |
| CY1105908T1 (el) | Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο | |
| WO2001078725A3 (en) | Modified release formulations containing a hypnotic agent | |
| NO20076083L (no) | Mukoadhesive xyloglukaninneholdende formuleringer som er anvendelige i medisinske anordninger og i farmasoytiske formuleringer | |
| KR970005279A (ko) | 소화관의 하부 부분에서 방출될 수 있는 피복 캡슐 형태의 약학 제제 | |
| DK1453487T3 (da) | Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud | |
| BR0114633A (pt) | Formulações farmacêuticas com liberação retardada | |
| BR0312347A (pt) | Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato | |
| DE69636724D1 (de) | Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe | |
| AR065072A2 (es) | Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo | |
| BR0007360A (pt) | Composição de liberação controlada | |
| DE60108255D1 (de) | Clarithromycin enthaltende zubereitung mit verlängerter freisetzung | |
| IS4772A (is) | Lyfjablöndur til inntöku um munn með breytta losun sem innihalda 5-ASA. | |
| PL402550A1 (pl) | Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika | |
| AR030099A1 (es) | Composicion de eletriptan en forma de particulas | |
| RU2009111866A (ru) | Композиция для ухода за зубным протезом | |
| MXPA04003540A (es) | Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo. | |
| MXPA04003506A (es) | Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn. | |
| PE20010568A1 (es) | Formulaciones orales de liberacion controlada | |
| YU66202A (sh) | Sistem za kontrolisano otpuštanje ciprofloksacina nakon oralne primene u jednoj dnevnoj dozi | |
| ATE245974T1 (de) | Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung | |
| UY26176A1 (es) | Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |